News Headlines

  1. Alteogen Announces Exclusive License Agreement With A Global Pharmaceutical Company For The Development And Commercialization Of A Hybrozyme™-Enabled Subcutaneous Biologic Product 8/7/2026

    Alteogen Inc. (KOSDAQ: 196170), a leading biopharmaceutical company specializing in platform technologies, announced today that it has entered into an exclusive license agreement with a global pharmaceutical company for the development and commercialization of a subcutaneous (SC) biologic product utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

  2. Energenesis Biomedical And Taiwan Tanabe Seiyaku Enter Joint Development Agreement For ENERGI-F703DFU 8/6/2026

    Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has entered into a joint development agreement with Taiwan Tanabe Seiyaku Co., Ltd. (Taiwan Tanabe), the wholly owned subsidiary of Tanabe Pharma Corporation, for ENERGI-F703DFU, Energenesis' investigational topical drug for diabetic foot ulcers (DFU).

  3. Northwest Biotherapeutics Announces MOU For Collaboration With The Saudi Pharmaceutical Industries And Medical Appliance Company 8/6/2026

    Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the Company's DCVax®-L products and technology to Saudi Arabia.

  4. Mediar Therapeutics Enters Into A Collaboration And Option Agreement With Ono Pharma To Develop Novel Treatments For Fibro-Inflammatory Diseases 8/6/2026

    Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, has entered into a collaboration and option agreement with Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono") for novel treatments targeting fibro-inflammatory diseases.

  5. CellFiber And Tidewave Bio Enter Collaboration To Evaluate Scalable 3D Manufacturing For Next-Generation Solid Tumor Immunotherapy 8/5/2026

    CellFiber Co., Ltd. (“CellFiber”), a Tokyo-based biotechnology company built on its proprietary CellFiber® cell encapsulation platform, and Tidewave Bio (“Tidewave”), a Los Angeles-based biotechnology company developing a universal, off-the-shelf immunotherapy platform for solid tumors, today announced a collaboration to evaluate CellFiber’s closed, automated 3D cell culture platform in support of the scalable manufacturing of Tidewave’s next-generation cell immunotherapy.

  6. Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services To Commercialization 8/5/2026

    Recently, Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA).

  7. Evexta Bio Announces Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate Rupitasertib In Combination With A Selective Estrogen Receptor Degrader In Advanced / Metastatic Breast Cancer 8/4/2026

    Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer.

  8. Myellama Therapeutics And Vaxcellbio Sign MOU 8/4/2026

    Myellama Therapeutics has signed a strategic memorandum of understanding with Korean biotechnology company Vaxcellbio to co-develop therapies for multiple myeloma and other indications using its next-generation trispecific engager technology, developed with the National Research Council Canada (NRC).

  9. Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, In Non-Small Cell Lung Cancer 8/4/2026

    Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has entered into a Clinical Trial Collaboration and Supply Agreement (“CTCSA”) with Eli Lilly & Company (“Lilly”), to evaluate the combination of Amplia’s investigational FAK inhibitor, narmafotinib, with Lilly’s investigational KRAS G12C inhibitor, olomorasib.

  10. Wacker Biotech And Eclipsebio Announce Strategic Collaboration To Advance RNA Medicine Development And Production 8/4/2026

    Wacker Biotech, a leading contract development and manufacturing organization (CDMO) wholly owned by Wacker Chemie AG, and Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced a strategic collaboration.